Cargando…

The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer

BACKGROUND: This study was conducted to propose the optimal duration of fluoropyrimidine-based adjuvant chemotherapy consisting of fluoropyrimidine derivatives alone or combined with intravenous platinum for stage II or III gastric cancer (GC). METHODS: We analyzed retrospectively the data from 2219...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seong-Geun, Hwang, Sun-Hwi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818924/ https://www.ncbi.nlm.nih.gov/pubmed/27039375 http://dx.doi.org/10.1186/s12957-016-0845-1

Ejemplares similares

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
por: Min, Byung-Hoon, et al.
Publicado: (2011)

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis
por: Boyne, Devon J., et al.
Publicado: (2019)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer
por: SU, YUQI, et al.
Publicado: (2015)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2019)

Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Li, Chao, et al.
Publicado: (2022)

Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
por: Boyne, Devon J., et al.
Publicado: (2021)

Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery
por: Chang, Shin-Chun, et al.
Publicado: (2018)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2020)

The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
por: Shih, Yu-Hsuan, et al.
Publicado: (2023)

Retracted: Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
por: Huang, Ching-Wen, et al.
Publicado: (2021)

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
por: Wu, Lili, et al.
Publicado: (2021)

Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I‐II or unresected stage III pancreatic cancer
por: Ma, Sung J., et al.
Publicado: (2019)

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer
por: Yuan, Shu‐Qiang, et al.
Publicado: (2023)

Outcomes of Adjuvant Oral versus Intravenous Fluoropyrimidines for High-Risk Stage II or Stage III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study
por: Zhang, Jiaqiang, et al.
Publicado: (2020)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

A Prognostic Nomogram and Heat Map to Predict Survival in Stage II/III Gastric Cancer Patients After Curative Gastrectomy Followed by Adjuvant Chemotherapy
por: Shi, Litong, et al.
Publicado: (2022)

Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer
por: Wang, Yizhuo, et al.
Publicado: (2016)

Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
por: Hirahara, Noriyuki, et al.
Publicado: (2021)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
por: Kim, Young Saing, et al.
Publicado: (2017)

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer
por: Mobayed, Mohammad, et al.
Publicado: (2009)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

HLA-G 3’UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment
por: Garziera, Marica, et al.
Publicado: (2015)

A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer
por: Chan, Jason, et al.
Publicado: (2013)

The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma
por: Zhao, Zhuang, et al.
Publicado: (2020)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy
por: Kim, Yeul Hong, et al.
Publicado: (2012)

DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer
por: Fan, Zhiyuan, et al.
Publicado: (2022)

Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer
por: Ichikawa, Wataru, et al.
Publicado: (2016)

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
por: Lau, David, et al.
Publicado: (2020)

Association between adjuvant chemotherapy and survival in stage I gastric cancer patients after curative resection
por: Chen, Qiuying, et al.
Publicado: (2023)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
por: Gao, Peng, et al.
Publicado: (2018)

Postoperative Adjuvant Chemoradiotherapy Versus Chemotherapy Alone for Stage III Endometrial Cancer: A Multicenter Retrospective Study
por: Yoo, Ji Geun, et al.
Publicado: (2022)

Optimal Duration of Adjuvant Chemotherapy for Gastric Cancer: Might Less Be More?
por: Han, Hye Sook
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jmmv2f0jdiue4mhpoouchrlbfs